Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dyadic International ( (DYAI) ) has shared an update.
On June 23, 2025, Dyadic International received a deficiency notice from Nasdaq due to its failure to maintain a minimum market value of $35 million for 30 consecutive business days. The company has until December 20, 2025, to comply with Nasdaq’s listing requirements or face potential delisting, and it plans to monitor and address the issue to regain compliance.
The most recent analyst rating on (DYAI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dyadic International stock, see the DYAI Stock Forecast page.
Spark’s Take on DYAI Stock
According to Spark, TipRanks’ AI Analyst, DYAI is a Neutral.
Dyadic International’s overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock’s technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.
To see Spark’s full report on DYAI stock, click here.
More about Dyadic International
Dyadic International, Inc. operates in the biotechnology industry, focusing on the development and production of enzymes and other proteins for various markets, including pharmaceuticals, biofuels, and industrial enzymes.
Average Trading Volume: 35,331
Technical Sentiment Signal: Sell
Current Market Cap: $29.58M
Find detailed analytics on DYAI stock on TipRanks’ Stock Analysis page.